From the publishers of JADPRO

MPN Resource Center

Advertisement

Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review

Last Updated: Friday, September 2, 2022

In a real-world review of medical records of patients with myelofibrosis treated with ruxolitinib, estimated median survival from treatment initiation was 44.4 months (95% CI: 38.8–50.2 months), and 23% of patients continued ruxolitinib after disease progression.

Future Oncology
Advertisement
News & Literature Highlights
Advertisement
Advertisement